Protagonist Therapeutics Inc (PTGX)
41.08  +0.70 (1.73%)

Protagonist Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapeutic solutions for patients suffering from a range of serious diseases. The company employs a unique approach that combines peptide-based drug discovery with advanced technologies to create targeted therapies, aiming to address unmet medical needs in areas such as gastrointestinal conditions, inflammatory diseases, and oncology. With a commitment to scientific rigor and collaboration, Protagonist is advancing its pipeline of drug candidates through clinical trials, striving to bring new treatments to market that can significantly improve patient outcomes.

SummaryNewsPress ReleasesChartHistorical
Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Fridaybenzinga.com
Via Benzinga · November 22, 2024
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · November 13, 2024
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opinesbenzinga.com
Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Phase 2 data in rare blood cancer and a multi-billion dollar potential.
Via Benzinga · September 10, 2024
PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024investorplace.com
PTGX stock results show that Protagonist Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 6, 2024
The Latest Analyst Ratings for Protagonist Therapeuticsbenzinga.com
Via Benzinga · November 3, 2023
What 6 Analyst Ratings Have To Say About Protagonist Therapeuticsbenzinga.com
Via Benzinga · September 25, 2023
Expert Ratings for Protagonist Therapeuticsbenzinga.com
Via Benzinga · July 6, 2023
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?benzinga.com
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%
Via Benzinga · July 28, 2024
AT&T, Group 1 Automotive, Mattel, Seagate And Other Big Stocks Moving Higher On Wednesdaybenzinga.com
Via Benzinga · July 24, 2024
3 Growth Stocks No One Is Watching (But They Should Be)investorplace.com
While overlooked growth stocks present high risks, it’s difficult to find any other sector with as much upside potential.
Via InvestorPlace · July 11, 2024
Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600investors.com
Protagonist Therapeutics will join the SmallCap 600 on Wednesday.
Via Investor's Business Daily · June 28, 2024
The 3 Best Biotech Stocks to Buy in June 2024investorplace.com
Explore the best biotech stocks to buy in June 2024, with insights on Protagonist, BridgeBio and Intellia.
Via InvestorPlace · June 5, 2024
PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024investorplace.com
PTGX stock results show that Protagonist Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 7, 2024
Why Is Japanese Drugmaker Takeda Stock Trading Lower Today?benzinga.com
Takeda Pharmaceutical's Q3 2023 results: ¥235.9 billion core net profit, management changes, and a global collaboration deal for rusfertide. Fiscal year 2023 guidance reiterated.
Via Benzinga · February 1, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga.com
Via Benzinga · January 31, 2024
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most Onfool.com
Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.
Via The Motley Fool · November 16, 2023
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarterbenzinga.com
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via Benzinga · July 27, 2023
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursdayinvestorplace.com
We're starting off Thursday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning.
Via InvestorPlace · July 13, 2023
Analyst Boosts Protagonist Therapeutics Price Target, Says Psoriasis Data Impressivebenzinga.com
JMP Securities has increased the price target for Protagonist Therapeutics Inc (NASDAQ: PTGX) from $28 to $35, 
Via Benzinga · July 6, 2023
Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursdaybenzinga.com
Morgan Stanley cut the price target for ArcBest Corporation (NASDAQ: ARCB) from $136 to $125. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. ArcBest shares fell 3.3% to close at $95.42 on Wednesday.
Via Benzinga · July 6, 2023
Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatmentbenzinga.com
Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from the Phase 2b FRONTIER 1 trial of the oral interleukin-23 receptor (IL-23R) antagonist JNJ-2113 (formerly PN-235) in adult patients with moderate-to-severe plaque psoriasis presented at World Congress of 
Via Benzinga · July 5, 2023
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga.com
Via Benzinga · July 4, 2023
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · July 3, 2023
Why Li Auto Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Sessionbenzinga.com
Gainers PolyMet Mining Corp. (NYSE: PLM) shares surged 144% to $1.92 after the company announced Glencore made a non-binding proposal to acquire the company for $2.11 per share.
Via Benzinga · July 3, 2023
AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Mondaybenzinga.com
U.S. stocks traded mixed, with the Dow Jones dropping around 30 points on Monday. Here are some big stocks recording losses in today’s session. Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares dipped 36.4% to $17.60.
Via Benzinga · July 3, 2023